Precision medicines to match the complexity of the human brain. Backed by Third Rock Ventures.
About the role
As the regulatory lead for RAP-219 and Bipolar Mania trials, you’ll help shape the path from promising science to a potential treatment for patients. You’ll work closely with the program team to develop regulatory strategies, navigate complex decisions, and translate evolving agency expectations into actionable plans. This is a hands on role that requires both big picture thinking and a willingness to dig into the details, challenge assumptions, and work through problems alongside your colleagues. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Bachelor’s degree in a life science or related discipline
- 12+ years of experience in the pharmaceutical or biotech industry, with progressive responsibility in regulatory strategy
- Experience leading regulatory strategy for a development program, neurology or psychiatry and small molecules preferred
- Demonstrated experience navigating late-stage development and contributing to the preparation and submission of an NDA
- Experience working with Office of Neuroscience FDA Divisions, including leading health authority interactions
- Global drug development experience
More about this role
When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we’re driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we’re doing this with extraordinary science and awesome people (affectionately called Rapptors).
Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder.
The strength of Rapport comes from our Rapptors – who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you’re as...
Browse similar: Startup jobs